Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hematol Oncol ; 25(4): 164-9, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17577204

RESUMO

Osteonecrosis of the jaws (ONJ) associated with the use of bisphosphonates is a newly described entity. To elucidate the mechanism leading to ONJ and to test the hypothesis that in patients with ONJ the bisphosphonates may interfere with endothelial cell proliferation, using flow cytometric analysis we evaluated the number of circulating endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) in eight patients with bisphosphonate treatment and osteonecrosis, eight multiple myeloma (MM) patients with bisphosphonates treatment without ONJ and five normal subjects. MM patients showed an increase of CD34+ cells with respect the control subjects and ONJ subjects. EPCs and CECs were higher in MM patients compared to controls and ONJ patients. ONJ patients showed a decrease of EPCs compared to control subjects while CECs were similar to the controls group. Our results seem to show the possibility that bisphosphonates could have a antiangiogenic effect and a suppressive effect on CECs of patients with ONJ.


Assuntos
Difosfonatos/efeitos adversos , Células Endoteliais/patologia , Doenças Maxilomandibulares/induzido quimicamente , Osteonecrose/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Inibidores da Angiogênese , Sangue , Estudos de Casos e Controles , Contagem de Células , Feminino , Citometria de Fluxo , Humanos , Masculino , Pessoa de Meia-Idade , Células-Tronco/patologia
2.
Acta Haematol ; 117(3): 181-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17164581

RESUMO

Osteonecrosis of the jaw is an unremitting adverse outcome associated with bisphosphonate therapy in patients with multiple myeloma or bone metastases from solid tumors. Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure. The discontinuation of bisphosphonate therapy has not helped reverse the presence of osteonecrosis, and the surgical manipulation of the involved site appears to worsen the underlying bone pathology. Hyperbaric oxygen, which has proven efficacious in other forms of osteonecrosis by establishing an oxygen gradient, is of no definitive benefit to patients with bisphosphonate-induced exposed bone. Antibiotic therapy is useful in controlling pain and swelling but ineffective in preventing the progression of the exposed bone. To date, prevention is the only currently possible therapeutic approach to the management of this complication.


Assuntos
Conservadores da Densidade Óssea/efeitos adversos , Neoplasias da Mama/complicações , Difosfonatos/efeitos adversos , Imidazóis/efeitos adversos , Mieloma Múltiplo/complicações , Osteonecrose/induzido quimicamente , Osteonecrose/etiologia , Alendronato/efeitos adversos , Neoplasias Ósseas/secundário , Neoplasias da Mama/patologia , Feminino , Humanos , Doenças Maxilomandibulares/induzido quimicamente , Doenças Maxilomandibulares/etiologia , Doenças Maxilomandibulares/patologia , Masculino , Mandíbula/diagnóstico por imagem , Mandíbula/patologia , Maxila/diagnóstico por imagem , Maxila/patologia , Pessoa de Meia-Idade , Necrose , Osteonecrose/patologia , Pamidronato , Tomografia Computadorizada por Raios X , Ácido Zoledrônico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...